Bionyra was founded by Frédéric Marrache in 2025.

Who are Bionyra's investors?

Bionyra's investors include Jeito Capital, Sanofi Ventures, Sofinnova Partners, VIVES Partners, Apollo Health Ventures, Sixty Degree Capital.

How much funding has Bionyra raised?

Bionyra has disclosed $165M raised across 1 round.

Bionyra

Founded 2025 · 7 employees on LinkedIn · 7 known investors

Find your way into Bionyra

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.

Biotech Healthtech

Founders & leadership

Bionyra was founded in 2025 by Frédéric Marrache.

Frédéric MarracheCo-founder & CEO

Investors · 7

Jeito Capital✓ confirmed by BionyraParis

How we know: the company's own site · funding news · allsci.com · Not right? Tell us

Sanofi Ventures✓ confirmed by BionyraCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the company's own site · a partner's Signal profile · allsci.com · Not right? Tell us

Sofinnova Partners✓ confirmed by BionyraParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · the company's own site · funding news · allsci.com · Not right? Tell us

VIVES Partners✓ confirmed by BionyraWavre · $108K – $7.6M

How we know: VIVES Partners's portfolio page · the company's own site · allsci.com · Not right? Tell us

Apollo Health Ventures✓ confirmed by BionyraBerlin

How we know: the company's own site · allsci.com · Not right? Tell us

Sixty Degree Capital✓ confirmed by BionyraNorth York

How we know: the company's own site · allsci.com · Not right? Tell us

Also in the syndicate · 1

Arkin Bio

Funding

SEC filings, press & company announcements

$165M disclosed across 1 round · 2026

$165MSeries AJun 2026 · 5 sources
Jeito Capital (lead), Sofinnova Partners (lead), Apollo Health Ventures, Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

France's Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics | EU-Startupseu-startups.com · Jun 2026

Bionyra Pharma Raises $165M in Series A Fundingfinsmes.com · Jun 2026

Frequently asked questions

What does Bionyra do?: Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease. Its pipeline includes TL1A, TL1A*IL-23p19 bispecific, and IL-25 antibodies with half-life extension technology.
Who founded Bionyra?: Bionyra was founded by Frédéric Marrache in 2025.
Who are Bionyra's investors?: Bionyra's investors include Jeito Capital, Sanofi Ventures, Sofinnova Partners, VIVES Partners, Apollo Health Ventures, Sixty Degree Capital.
How much funding has Bionyra raised?: Bionyra has disclosed $165M raised across 1 round.